0001213900-22-063616.txt : 20221012
0001213900-22-063616.hdr.sgml : 20221012
20221012201534
ACCESSION NUMBER: 0001213900-22-063616
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221011
FILED AS OF DATE: 20221012
DATE AS OF CHANGE: 20221012
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schneiderman Daniel H
CENTRAL INDEX KEY: 0001565536
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40804
FILM NUMBER: 221307850
MAIL ADDRESS:
STREET 1: 760 PARKSIDE AVE. SUITE 304
STREET 2: SUITE 207
CITY: BROOKLYN
STATE: NY
ZIP: 11226
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pasithea Therapeutics Corp.
CENTRAL INDEX KEY: 0001841330
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851591963
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2110 NARCISSUS CT
CITY: VENICE
STATE: CA
ZIP: 90291
BUSINESS PHONE: 8184226172
MAIL ADDRESS:
STREET 1: 2110 NARCISSUS CT
CITY: VENICE
STATE: CA
ZIP: 90291
4
1
ownership.xml
X0306
4
2022-10-11
0
0001841330
Pasithea Therapeutics Corp.
KTTA
0001565536
Schneiderman Daniel H
1111 LINCOLN ROAD, SUITE 500
MIAMI BEACH
FL
33139
0
1
0
0
Chief Financial Officer
Stock Option (to acquire Common Stock)
1.26
2022-10-11
4
A
0
300000
0
A
2023-10-11
2032-10-11
Common Stock
300000
300000
D
The Reporting Person was granted 300,000 stock options. The stock options have a ten-year term and vest over three years, subject to Mr. Schneiderman remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches monthly for two years thereinafter.
/s/ Daniel Schneiderman
2022-10-12